Review of past and present clinical cases with a view to future treatment options

Future Oncol. 2017 Jun;13(13s):11-28. doi: 10.2217/fon-2017-0120. Epub 2017 May 2.


In the 10 years that have elapsed since trabectedin was first granted approval in Europe for treatment of advanced soft tissue sarcoma (STS), other cytotoxic agents and targeted therapies have been approved and numerous randomized controlled trials have been completed or are underway. As an academic exercise and positive proof of the advances in STS management that have occurred during the past decade, it is interesting to compare current and future treatment approaches. In this review, present and future treatment approaches are examined by case study for three STS subtypes: uterine leiomyosarcoma, abdominal dedifferentiated liposarcoma and malignant solitary fibrous tumor.

Keywords: dedifferentiated liposarcoma; solitary fibrous tumor; trabectedin; uterine leiomyosarcoma.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Clinical Decision-Making
  • Clinical Trials as Topic
  • Humans
  • Sarcoma / diagnosis*
  • Sarcoma / mortality
  • Sarcoma / therapy*
  • Survival Analysis
  • Treatment Outcome


  • Antineoplastic Agents